Targovax ASA: Annual Report 2017

15.03.18 07:05
Targovax ASA: Annual Report 2017

On 14 March 2018, the board of directors of Targovax ASA approved the company's financial statements for 2017, which will be dealt with by the Company's annual general meeting on 11 April 2018. The company's annual accounts for the financial year 2017, including the financial statements and annual report for the financial year 2017, are together with the auditor's report, attached to this notice and is also available at the company's webpage, www.targovax.com.

For further information, please contact:

Renate Birkeli, Investor Relations

Phone: +47 922 61 624

Email: renate.birkeli@targovax.com 

Media and IR enquires:

Andreas Tinglum - Corporate Communications (Norway)

Phone: +47 9300 1773

Email: andreas.tinglum@corpcom.no

Simon Conway - FTI Consulting (International)

Phone: +44 20 3727 1000

Email: Targovax@fticonsulting.com   

About Targovax

Arming the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

The Company's development pipeline is based on two novel proprietary platforms:

The first platform, ONCOS, uses oncolytic viruses as potential multi-target, neo-antigen, therapeutic cancer vaccines. ONCOS uses an adenovirus that has been engineered to be an immune activator that selectively targets cancer cells. In phase I trials it has demonstrated immune activation at tumor lesional level which was associated with clinical benefit. In an ongoing phase I combination trial in advanced melanoma we are seeking important proof of concept data to confirm that patients who have become refractory to treatment with a checkpoint inhibitor (CPI) can respond to the same checkpoint inhibitor after treatment with ONCOS-102.

The second platform, TG, uses neo-antigen cancer vaccines designed to specifically treat tumors that express mutated forms of RAS. Mutations to the RAS protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TG platform's therapeutic potential stems from its ability to enable the patient's immune system to develop a cellular response with the potential to identify and destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TG platform from a clinical trial of TG01 in resected pancreatic cancer patients showed encouraging overall survival.  These results are now providing guidance for the future clinical development of this platform.

Targovax's clinical development pipeline includes three novel therapeutic candidates covering six indications.

Both platforms are protected by an extensive portfolio of Intellectual Property (IP) and know-how and have the potential to yield multiple pipeline candidates in a cost-effective manner. Additionally, Targovax has other product candidates in preclinical development.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Targovax Annual Report 2017

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Targovax ASA via Globenewswire


Breaking News

Kurs- und weitere Informationen zum Thema:


Aktuelle Diskussionen zum Thema:

Aktuelle Nachrichten zum Unternehmen:

Viren gegen Krebs – Welche Aktie. (28.07.17)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Weitere Meldungen
15.03 Neste Corporation - Notificat.
15.03 Neste Corporation - Notificat.
15.03 Neste Corporation - Notificat.
15.03 Ad hoc: GxP German Prope.
15.03 Systemair AB Interim Repor.
15.03 NN Group published 2017 A.
15.03 DNO Releases 2017 Annual.
15.03 Neste Corporation's disposal .
15.03 Wentworth Resources Limite.
15.03 Ad hoc: Munich Re beschlie.
15.03 Targovax ASA: Notice of A.
15.03 Targovax ASA: Annual Rep.
15.03 GO Sport partners with Inge.
15.03 BOURBON: 2017 Annual Re.
15.03 Sanofi successfully prices E.
14.03 Ad hoc: Deutsche Rohstoff .
14.03 Ad hoc: 3W Power S.A. /.
14.03 Virbac : operating profit fro.
14.03 Ad hoc: Zapf Creation AG: .
14.03 Stolt-Nielsen Limited Publishe.
14.03 CapMan Group changes its .
14.03 Bombardier Transportation: B.
14.03 Decisions of the organising .
14.03 SpareBank 1 SMN : Trading.
14.03 Ad hoc: HOCHTIEF Aktieng.
14.03 Sampo plc: Disclosure Under.
14.03 Decisions of the Annual Ge.
14.03 Kamux Oyj: Kamux Corpora.
14.03 Decision on Ahtium's bankru.
14.03 DBV Technologies Reports .

Welche Social Networks nutzen Sie meistens?
Linked in

Stimmen: 50751 , Ergebnis

Status: nicht eingeloggt

Registrieren | Passwort vergessen?
Im Bereich Nachrichten:
Daytrading: Jeden Tag Gewinne?
Experte: Stefan Hofmann, STOCK-WORLD
Bitcoin/Ethereum - ...
Philip Hopf, Hopf Klinkmüller Capital. (26.06.19)
Experte: Philip Hopf, Hopf Klinkmüller Capital Management K.
Technische-X-Analyse.de ...
Devin Sage, Technische-X-Analyse.de (26.06.19)
Experte: Devin Sage, Technische-X-Analyse.de
DOW DAX seitwärts in ...
Thomas Heydrich, Systemstradings.de (26.06.19)
Experte: Thomas Heydrich, Systemstradings.de
DAX kann Gewinne nicht ...
CMC Markets, (26.06.19)
Experte: CMC Markets,
DAX dreht wieder nach ...
Christian Zoller, www.boerse-daily.de (26.06.19)
Experte: Christian Zoller, www.boerse-daily.de
Continental: Mit so guten ...
Volker Gelfarth, (26.06.19)
Experte: Volker Gelfarth,
Michael Beck, Leiter Po., Bankhaus ELLWANGER. (26.06.19)
Experte: Michael Beck, Leiter Portfolio M., Bankhaus ELLWANGER & GEIGER K.
Gazprom Pjsc ...
Robert Sasse, (26.06.19)
Experte: Robert Sasse,
Hitzedax - Anleger vor ...
Cornelia Frey, Börse Stuttgart AG (26.06.19)
Experte: Cornelia Frey, Börse Stuttgart AG
Illinois legalisiert als elfter ...
Björn Junker, GOLDINVEST.de (26.06.19)
Experte: Björn Junker, GOLDINVEST.de
DAX – spannende Seitwärts-...
Feingold-Research, (26.06.19)
Experte: Feingold-Research,
Goldaktien relativ stabil
Martin Siegel, STABILITAS FONDS (26.06.19)
Experte: Martin Siegel, STABILITAS FONDS
Niquet's World
Neues vom Portal
Woran liegt es, dass sich viele Trading-Neulinge finanziell ruinieren
Letzte Börsen-Meldung
Letzte Börsen-Analyse
Top-Klicks News
Top-Klicks Analysen